Side-effects of antituberculosis drug treatment in patients with chronic renal failure

S. J. Quantrill, M. A. Woodhead, C. E. Bell, C. C. Hardy, A. J. Hutchison, R. Gokal

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Patients with chronic renal failure (CRF) have a high incidence of tuberculosis (TB). Those from the Indian subcontinent are at particular risk. The frequency of side-effects associated with antituberculous treatment in a group of patients with CRF was studied. All cases of TB in patients with CRF occurring over a 13-yr period at the Manchester Royal Infirmary, from 1986-1999, were identified by diagnostic coding, microbiology records and a TB database. The case notes were then reviewed. Twenty-four cases were identified, eight predialysis and 16 requiring regular dialysis. TB occurring in the dialysis group was extrapulmonary in every case. Nineteen of 24 (79%) patients were of Indian subcontinent origin and 14 of 16 (87%) dialysis patients were non-Caucasian. Adverse effects of treatment occurred in two of eight (25%) in the predialysis group and nine of 16 (56%) of the dialysis group. These were most commonly neuropsychiatric (6), hepatic (4) and gastrointestinal (4). Neuropsychiatric symptoms occurred exclusively in dialysis patients. In conclusion, a high incidence of side-effects from antituberculous medication, especially neuropsychiatric, hepatic and gastrointestinal, was identified in patients with chronic renal failure. Careful monitoring for side-effects is essential in this group, and consideration should be given to administering antituberculous chemoprophylaxis to all high-risk groups.
    Original languageEnglish
    Pages (from-to)440-443
    Number of pages3
    JournalEuropean Respiratory Journal
    Volume20
    Issue number2
    DOIs
    Publication statusPublished - 2002

    Keywords

    • Chronic renal failure
    • Dialysis
    • Side-effects
    • Tuberculosis

    Fingerprint

    Dive into the research topics of 'Side-effects of antituberculosis drug treatment in patients with chronic renal failure'. Together they form a unique fingerprint.

    Cite this